ProMIS Neurosciences Inc.
(NASDAQ:PMN) reported positive blinded six-month interim safety and biomarker results from its ongoing Phase 1b PRECISE-AD trial evaluating lead drug candidate PMN310 in patients with mild cognitive impairment due to Alzheimer’s disease.
The clinical-stage biopharmaceutical company develops therapies targeting toxic misfolded proteins linked to neurodegenerative diseases.
Favorable Safety Profile Across Genotypes The blinded interim analysis included 136 Alzheimer’s disease patients and showed a favorable safety profile across all genotypes.
No cases of amyloid-related imaging abnormalities with edema (ARIA-E) were reported as of the data cutoff date.
